A PILOT STUDY OF PENTOXIFYLLINE IN REDUCING SYSTEMIC INFLAMMATION AND IMPROVING

己酮可可碱减少和改善全身炎症的初步研究

• 批准号: 7717581
• 负责人: SAMIR KUMAR GUPTA
• 金额: $ 0.02万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7717581
• 关键词: Academic Medical Centers; CD4 Lymphocyte Count; Cardiovascular system; Computer Retrieval of Information on Scientific Projects Database; Enrollment; Functional disorder; Funding; Grant; Immunologics; Indiana; Individual; Inflammation; Institution; Label; Measures; Mediating; Patients; Pentoxifylline; Phosphodiesterase Inhibitors; Pilot Projects; Research; Research Personnel; Resources; Safety; Source; TNF gene; Tumor Necrosis Factor-alpha; Tumor Necrosis Factors; United States National Institutes of Health; Upper arm; Week; antiretroviral therapy; human TNF protein; improved; prospective

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a prospective, single center, single arm, open-label, pilot study evaluating the potential efficacy and safety of pentoxifylline (PTX), a phosphodiesterase inhibitor that blocks tumor necrosis factor-? (TNF-?), in the treatment of endothelial dysfunction in twelve HIV-infected patients seen at the Indiana University Medical Center with CD4 cell counts greater than 350/¿L and not currently receiving antiretroviral therapy. Enrolled subjects will have their brachial flow-mediated dilation (FMD), a measure of endothelial function, and other cardiovascular and immunologic parameters measured at baseline and again after 4 and 8 weeks of treatment with PTX. Each individual subject will be followed for approximately 10 weeks. The total duration of this study will be approximately 8 months.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以出现在其他 CRISP 条目中 列出的机构是。 对于中心来说，它不一定是研究者的机构。 这是一项前瞻性、单中心、单臂、开放标签的试点研究，评估己酮可可碱 (PTX)（一种阻断肿瘤坏死因子 (TNF-α) 的磷酸二酯酶抑制剂）治疗内皮细胞癌的潜在功效和安全性。印第安纳大学医学中心发现 12 名 HIV 感染者的 CD4 细胞计数超过 350/¿ L 且目前未接受抗逆转录病毒治疗的受试者将在基线时以及在 PTX 治疗 4 周和 8 周后再次测量肱动脉血流介导的扩张 (FMD)、内皮功能指标以及其他心血管和免疫学参数。个别受试者将被跟踪约 10 周，这项研究的总持续时间约为 8 个月。